… a significant prolongation of PFS versus gefitinib. Vandetanib 300 mg/d is currently being
evaluated as a monotherapy in two randomized phase III studies in advanced NSCLC. …

… Because gefitinib has shown clinical benefit in other squamous cell carcinomas and … in
preclinical studies, we designed a phase II trial to evaluate the efficacy of gefitinib in aggressive …

… Gefitinib has shown an acceptable side-effect profile in phase I studies [9–11] and therapeutic
activity in several phase II studies of several systemic cancers [12,13], leading to recent …

… significantly improved PFS compared with placebo and there was a trend in favor of
gefitinib in terms of OS. This proof of principle randomized phase II study confirms that poor PS …

… in studying statins as a potential EGFR-targeted therapeutic intervention. This is the first
randomized phase II study comparing the efficacy of gefitinib plus simvastatin versus gefitinib …

… These two EGFR TKIs produced similar results for RR, OS, and toxicity. To some extent, the
… study was almost the same as that of the earlier randomised phase II study, in which gefitinib …

… of phase II studies showing response in refractory patients. In other phase II studies of gefitinib,
… activity and responses in phase I, and the urgent need for new approaches for HRPC, a …

… This single-arm, phase II clinical trial recruited patients at nine institutes in north-eastern …
examined in future randomised phase III trials, our results clearly demonstrated that gefitinib has …

… 10.4% and 53%, respectively, indicating that gefitinib has single-agent activity in head and
neck … , phase II study was conducted to assess the safety/tolerability and efficacy of gefitinib in …

… randomized phase II trial assessed tamoxifen plus placebo or the epidermal growth factor
receptor inhibitor gefitinib … A 5% or more improvement in response variables with gefitinib was …